Posted in | Nanobusiness

Amgen Acquires BioVex Group

Harris & Harris Group, Inc. (Nasdaq:TINY) notes that Amgen and BioVex Group, Inc., today announced the completion of the acquisition of BioVex Group, Inc.

The transaction provides Amgen with BioVex's lead product candidate, OncoVEXGM-CSF, a novel investigational oncolytic vaccine in Phase 3 clinical development that may represent a new approach to treating melanoma and head and neck cancer. The acquisition was initially announced on January 24, 2011.

Harris & Harris Group was an investor in privately held BioVex Group. Harris & Harris Group made its initial investment in BioVex Group in September 2007.

Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems.

Source: http://www.hhvc.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Harris and Harris Group. (2019, February 12). Amgen Acquires BioVex Group. AZoNano. Retrieved on December 06, 2019 from https://www.azonano.com/news.aspx?newsID=21859.

  • MLA

    Harris and Harris Group. "Amgen Acquires BioVex Group". AZoNano. 06 December 2019. <https://www.azonano.com/news.aspx?newsID=21859>.

  • Chicago

    Harris and Harris Group. "Amgen Acquires BioVex Group". AZoNano. https://www.azonano.com/news.aspx?newsID=21859. (accessed December 06, 2019).

  • Harvard

    Harris and Harris Group. 2019. Amgen Acquires BioVex Group. AZoNano, viewed 06 December 2019, https://www.azonano.com/news.aspx?newsID=21859.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit